Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
IOVANCE BIOTHERAPEUTICS, INC. Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.	United States of America	IOVA
Ipsen Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.	France	IPN
IRLAB Therapeutics Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.	Sweden	IRLAB
IRONWOOD PHARMACEUTICALS INC Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.	United States of America	IRWD
ISU Abxis Co., Ltd. Developing antibody-based immunotherapies for oncology and rare diseases.	South Korea	086890
Iterum Therapeutics plc Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.	United States of America	ITRM
IVF HARTMANN Holding AG Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.	Switzerland	VBSN
Jade Biosciences, Inc. Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.	United States of America	JBIO
Jaguar Health, Inc. Develops plant-based, non-opioid GI therapies for humans and animals.	United States of America	JAGX
Janux Therapeutics, Inc. Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.	United States of America	JANX